Quality of Life Research

, 15:597

Impact of Fatigue in Parkinson’s Disease: The Fatigue Impact Scale for Daily Use (D-FIS)

Authors

    • Unit of Neuroepidemiology, National Centre for EpidemiologyISCIII (Madrid), The Spanish Network HOHSR
    • Unidad de Neuroepidemiología, Centro Nacional de EpidemiologíaInstituto de Salud Carlos III
  • Maria Jose Catalan
    • Department of NeurologySan Carlos University Teaching Hospital (Madrid)
  • Julian Benito-Leon
    • Department of NeurologyMostoles General Hospital (Madrid)
  • Angel Ortega Moreno
    • Department of NeurologyVirgen de las Nieves Hospital (Granada)
  • Ivana Zamarbide
    • Department of NeurologyFuenlabrada General Hospital (Madrid)
  • Esther Cubo
    • Department of NeurologyNuestra Señora del Rosario Clinic (Madrid)
  • Nadeje van Blercon
    • Department of NeurologyQuiron Clinic (San Sebastian)
  • Victor Campos Arillo
    • Department of NeurologyUniversity Teaching Hospital (Malaga)
  • Margarita Pondal
    • Department of NeurologySevero Ochoa Hospital (Leganes, Madrid)
  • Gurutz Linazasoro
    • Department of NeurologyQuiron Clinic (San Sebastian)
  • Fernando Alonso
    • Department of NeurologyFuenlabrada General Hospital (Madrid)
  • Pedro García Ruiz
    • Department of NeurologyJimenez Diaz Foundation (Madrid)
  • Belen Frades
    • Unit of Neuroepidemiology, National Centre for EpidemiologyISCIII (Madrid), The Spanish Network HOHSR
Article

DOI: 10.1007/s11136-005-4181-0

Cite this article as:
Martinez-Martin, P., Catalan, M.J., Benito-Leon, J. et al. Qual Life Res (2006) 15: 597. doi:10.1007/s11136-005-4181-0

Abstract

The Fatigue Impact Scale for Daily Use (D-FIS) was used in a cross-sectional study including 142 consecutive Parkinson’s disease (PD) patients. Usual clinical measures for PD, the Montgomery-Asberg Depression Rating Scale and the Parkinson’s Disease Questionnaire-8 items were applied. In addition to the D-FIS, patients with fatigue (67.6%, PWF) completed the Multidimensional Fatigue Inventory (MFI), a visual analogue scale for fatigue (VAS-F) and a Global Perception of Fatigue scale (GPF). Relevant psychometric D-FIS results were: floor effect = 4.2%; ceiling effect = 1.1%; skewness = 0.44; item homogeneity = 0.63; Cronbach’s α = 0.93; item-total correlation = 0.68 (item 1)−0.82 (item 8); standard error of measurement = 2.15; convergent validity with other fatigue measures = 0.54 [GPF]−0.62 [VAS-F] (p<0.001). In a multiple linear regression model, fatigue, depression, and disability independently influenced HRQoL, as measured by the PDQ-8. Patients on amantadine had lower prevalence of fatigue. In PD, D-FIS is a consistent and valid measure for fatigue, a frequent symptom previously found to impair patients’ HRQoL. Fatigue was also linked to depression and disability in this study.

Key words

AmantadineAssessmentD-FISFatigueParkinson’s diseasePsychometric attributesQuality of life

Abbreviations

FIS

Fatigue Impact Scale

D-FIS

Fatigue Impact Scale for daily use

GPF

Global Perception of Fatigue scale

HRQoL

Health-related quality of life

HY

Hoehn and Yahr Classification

ISAPD

Intermediate Scale for Assessment of Parkinson’s Disease

IR

Interquartile rank

MADRS

Montgomery-AsbergDepression Rating Scale

MFI

Multidimensional Fatigue Inventory

MFI-GF

Multidimensional Fatigue Inventory-General Fatigue

PD

Parkinson’s disease

PDQ-8

Parkinson’s Disease Questionnaire-8 Items

PDQ-8 SI

Parkinson’s Disease Questionnaire-8 Items Summary Index

PWF

Patients with fatigue

PNF

Patients without fatigue

SES

Schwab and England Scale

UPDRS

Unified Parkinson’s Disease Rating Scale

VAS-F

Visual analogue scale for fatigue

Copyright information

© Springer 2006